The Canada Lymph Node Score: A Feasibility Randomized Controlled Trial

NACompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

May 6, 2019

Primary Completion Date

March 2, 2020

Study Completion Date

June 8, 2020

Conditions
Non Small Cell Lung Cancer
Interventions
DIAGNOSTIC_TEST

Selective Targeted Sampling

After CLNS assessment, patients with proven malignant mediastinal lymph nodes will be referred for chemoradiation and patients with proven benign mediastinal lymph nodes will undergo surgical resection as per standard of care guidelines. Final pathology from the resected specimen will be considered the gold standard for analysis of sensitivity and specificity.

DIAGNOSTIC_TEST

Systematic Sampling

Following routine biopsy of lymph nodes, patients with proven malignant mediastinal lymph nodes will be referred for chemoradiation and patients with proven benign mediastinal lymph nodes will undergo surgical resection as per standard of care guidelines. Final pathology from the resected specimen will be considered the gold standard for analysis of sensitivity and specificity.

Trial Locations (1)

L8N 4A6

St. Joseph's Healthcare Hamilton, Hamilton

All Listed Sponsors
collaborator

McMaster University

OTHER

lead

St. Joseph's Healthcare Hamilton

OTHER

NCT03859349 - The Canada Lymph Node Score: A Feasibility Randomized Controlled Trial | Biotech Hunter | Biotech Hunter